Combining Bismuth-213 with Nanobodies: Finding the Perfect Match for Targeted Alpha Therapy
نویسندگان
چکیده
منابع مشابه
Targeted Alpha-Particle Immunotherapy with Bismuth-213 and Actinium-225 for Acute Myeloid Leukemia
Lintuzumab, a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest activity against acute myeloid leukemia (AML). To increase the antibody’s potency yet avoid nonspecific cytotoxicity seen with -emitting isotopes, lintuzumab was conjugated to the -emitters bismuth-213 (213Bi) and actinium-225 (225Ac). The 46-minute half-life of 213Bi limits its widespread use. Therefore...
متن کاملTargeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
INTRODUCTION The combination of a targeted biomolecule that specifically defines the target and a radionuclide that delivers a cytotoxic payload offers a specific way to destroy cancer cells. Targeted radionuclide therapy (TRNT) aims to deliver cytotoxic radiation to cancer cells and causes minimal toxicity to surrounding healthy tissues. Recent advances using α-particle radiation emphasizes th...
متن کاملSystemic Targeted Alpha Radiotherapy for Cancer
Background: The fundamental principles of internal targeted alpha therapy for cancer were established many decades ago.The high linear energy transfer (LET) of alpha radiation to the targeted cancer cellscauses double strand breaks in DNA. At the same time, the short range radiation spares adjacent normal tissues. This targeted approach complements conventional external beam radiotherapy and ch...
متن کاملA Perfect Match 1 Running head: A Perfect Match A Perfect Match: Decoding Employee Engagement
Engagement has been defined as “the harnessing of organization members’ selves to their work roles” (Kahn, 1990, p. 694). The main objective of this paper is to present the topic of engagement to performance improvement professionals. Specifically, this paper includes (a) engagement definitions and (b) job, organizational, leadership, and individual factors connected to engagement. Next, the au...
متن کاملCombining targeted therapy with immunotherapy (interferon-α)
Imatinib revolutionized gastrointestinal stromal tumor (GIST) treatment but median-progression-free-survival of unresectable/metastatic disease is < 2 y. B-RAF(V600)-mutated-melanoma responds to vemurafenib dramatically but median-progression-free-survival is < 9 mo. Combining imatinib with immunotherapy (peginterferon α-2b) in GIST showed significant induction of antitumor immunity and highly ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Medical Imaging and Radiation Sciences
سال: 2019
ISSN: 1939-8654
DOI: 10.1016/j.jmir.2019.03.024